D. Western Therapeutics Institute, Inc. (FRA:6DW)

Germany · Delayed Price · Currency is EUR

0.3120

-0.0040 (-1.27%)

Last updated: Oct 23, 2026, 8:06 AM CEST

Market Cap	20.97M -25.9%
Revenue (ttm)	1.33M -41.3%
Net Income	-3.44M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,790
Open	0.3120
Previous Close	0.3160
Day's Range	0.3120 - 0.3120
52-Week Range	0.3120 - 0.5600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About FRA:6DW

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 19

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 6DW

Financial Performance

In 2025, FRA:6DW's revenue was 387.00 million, a decrease of -17.83% compared to the previous year's 471.00 million. Losses were -632.00 million, -51.01% less than in 2024.

Financial numbers in JPY Financial Statements